Key Developments: CytRx Corporation Secures European Patent for Arimoclomol September 10, 2009 CytRx Corporation Receives FDA Letter Regarding Arimoclomol Phase IIb Clinical Trial For ALS September 8, 2009 CytRx Corporation's Arimoclomol Demonstrates Statistically Significant Cellular Evidence of Both Neuroprotection and Neuroregeneration in Animal Stroke Study August 24, 2009 CytRx Corporation's Drug Candidate INNO-206 Produces Statistically Significant Tumor Shrinkage in Animal Model of Small Cell Lung Cancer August 12, 2009 CytRx Corporation To Receive FDA Correspondence Regarding Clinical Development Of Arimoclomol In ALS August 6, 2009 CytRx Corporation's Drug Candidate INNO-206 Results In Ovarian Tumor Shrinkage In Animal Trials July 28, 2009 CytRx Corporation Receives Positive Opinion From Committee For Orphan Medicinal Products In European Union For Treatment of APL July 24, 2009 CytRx Corporation's INNO-206 Demonstrates Statistically Significant Tumor Shrinkage In Animal Trial For Breast Cancer July 13, 2009 CytRx Corporation Files Report With FDA In Response To Partial Clinical Hold On Its Phase 2b Arimoclomol ALS Trial June 30, 2009 CytRx Corporation Reports Favorable Progress Update For Its Pivotal Phase 2 Clinical Trial With Tamibarotene As Third-Line Treatment For Acute Promyelocytic Leukemia June 29, 2009 CytRx Corporation To Present Data From Its Chaperone Amplifying Drug Candidate Arimoclomol June 25, 2009 CytRx Corporation's Tamibarotene Demonstrates Statistically Significant Anti-Tumor Activity in Animal Trial for Multiple Myeloma June 17, 2009
$1.02 (10/20/09)
